Novartis Secukinumab’s Dosing To Be Key Issue At FDA Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Alternative doses in plaque psoriasis patients, including a higher dose than was studied in Phase III at Novartis’ panel for the IL-17 biologic, could be on the table during advisory committee.